NDA 021641 · Teva
Azilect
Rasagiline Mesylate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Jun 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
May 16, 2006
Approved uses
3
Original approval plus efficacy supplements
Registered trials
55
19 Phase 3, 0 recruiting
FAERS reports
11,264
7,507 serious, 1,255 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 30, 2020.
AZILECT (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD). AZILECT, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease ( 1 )
Mechanism: AZILECT is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease. The results of a clinical trial designed to examine the effects of AZILECT on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of AZILECT. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. MAO, a flavin-containing enzyme, is classified into two major molecular species, A and B, and is...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 2014 Supplement 17 · Efficacy LetterLabel
- Dec 9, 2009 Supplement 8 · Efficacy ReviewLetterLabel
- May 16, 2006 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
- AZILECT · RASAGILINE MESYLATE EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
- AZILECT · RASAGILINE MESYLATE EQ 0.5MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rasagiline" as an intervention, any sponsor and status, largest first.
- A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's DiseasePivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00256204 · 1,174 participants · Start Nov 2005 · Primary completion Apr 2008
Drug: Rasagiline Mesylate; Rasagiline Mesylate · For: Parkinson's Disease
- A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01155479 · 1,022 participants · Start Jul 6, 2010 · Primary completion Jul 16, 2013
Drug: Preladenant 2 mg tablet; Preladenant 5 mg tablet and 4 more · For: Parkinson Disease
- An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01215227 · 839 participants · Start Nov 18, 2010 · Primary completion Jul 16, 2013
Drug: Preladenant; Rasagiline and 2 more · For: Parkinson Disease; Idiopathic Parkinson Disease
- A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01155466 · 778 participants · Start Jul 14, 2010 · Primary completion Dec 20, 2012
Drug: Preladenant 2 mg tablet; Preladenant 5 mg tablet and 4 more · For: Parkinson Disease
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sPivotal-lookingCompleted
Pharma Two B Ltd.Industry
NCT03329508 · 544 participants · Start Jan 19, 2018 · Primary completion Aug 23, 2021
Drug: P2B001 0.6/0.75 mg; Rasagiline 0.75 mg and 2 more · For: Parkinson Disease; Early Parkinson's Disease
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 72 sites in all
- Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor FluctuationsPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00203034 · 472 participants · Start May 2000 · Primary completion Jan 2003
Drug: rasagiline mesylate; 1.0 mg rasagiline mesylate · For: Parkinson's Disease
Sites: Chicago, Illinois; New York, New York; Rochester, New York · 4 sites in all
- Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With LevodopaPivotal-lookingCompleted
Teva Neuroscience, Inc.Teva (TEVA)
NCT00203060 · 404 participants · Start Jul 1997 · Primary completion Jul 2000
Drug: Rasagiline Mesylate; placebo · For: Parkinson's Disease
- Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)Pivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT00104273 · 376 participants · Start Aug 2004 · Primary completion Mar 2007
Drug: Rasagiline · For: Dementia; Alzheimer's Disease
Sites: Huntsville, Alabama; Tucson, Arizona; Little Rock, Arkansas · 58 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall1,093
- hallucination986
- dyskinesia784
- drug ineffective772
- dizziness675
- tremor663
- death638
- confusional state561
- parkinson^s disease543
- gait disturbance536
- somnolence515
- nausea501
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 7 |
| 2007 | 66 |
| 2008 | 138 |
| 2009 | 95 |
| 2010 | 271 |
| 2011 | 268 |
| 2012 | 303 |
| 2013 | 437 |
| 2014 | 423 |
| 2015 | 590 |
| 2016 | 692 |
| 2017 | 897 |
| 2018 | 912 |
| 2019 | 1,045 |
| 2020 | 1,057 |
| 2021 | 911 |
| 2022 | 813 |
| 2023 | 521 |
| 2024 | 629 |
| 2025 | 634 |
| 2026 | 555 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azilect (Rasagiline Mesylate)
2024 spending
$1.4M
Beneficiaries
143
725 claims
Per beneficiary
$9,734
$36.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,330,711 |
| 2021 | $3,058,965 |
| 2022 | $2,670,658 |
| 2023 | $1,922,416 |
| 2024 | $1,391,907 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Agnieszka W, Pawe P, Magorzata K · Curr Neuropharmacol 2022 · Systematic Review
- Interventions for fatigue in Parkinson's disease.
Elbers RG, Verhoef J, van Wegen EE, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Systematic Review
- Rasagiline treatment effects on parkinsonian tremor.
Lew MF · Int J Neurosci 2013 · Multicenter Study, Randomized Controlled Trial
- Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
Poewe W, Hauser RA, Lang A · Mov Disord 2015 · Multicenter Study, Randomized Controlled Trial
- Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
Lim TT, Kluger BM, Rodriguez RL, et al. · Mov Disord 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.
Krismer F, Seppi K, Wenning GK, et al. · Parkinsonism Relat Disord 2019 · Multicenter Study, Randomized Controlled Trial
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.